Barclays
SLS icon

Barclays’s SELLAS Life Sciences SLS Stock Holding History

Barclays’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200,000
Closed -$754K – 5395
2025
Q4 		$754K Buy
+200,000
New +$389K ﹤0.01% 3620

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Barclays's SLS Position: Q1 2026 in Review

Barclays reduced its SELLAS Life Sciences (SLS) stake by 94% in Q1 2026, selling an estimated $2.14M and leaving 32,412 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #3894.

Barclays first reported a position in SLS in Q1 2017 and has held it in 8 quarters since. The position peaked at $1.93M in Q4 2025. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Barclays held 32,412 shares of SELLAS Life Sciences worth $137K as of Q1 2026.
  • Barclays sold 478,622 SELLAS Life Sciences shares in Q1 2026, an estimated $2.14M.
  • SELLAS Life Sciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3894 holding.
  • Barclays first reported a position in SELLAS Life Sciences in Q1 2017 and has held it in 8 quarters since.
  • Barclays's SELLAS Life Sciences position peaked at $1.93M in Q4 2025.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.